Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: A case-control study

被引：2
|
作者：
Alessandria, C. [1 ]
Debernardi-Venon, W. [1 ]
Todros, L. [1 ]
Rizzetto, M. [1 ]
Marzano, A. [1 ]
机构：
[1] San Giovanni Battista Hosp, Div Gastroenterol & Hepatol, Turin, Italy
来源：
JOURNAL OF HEPATOLOGY | 2007年 / 46卷
关键词：
D O I：
10.1016/S0168-8278(07)61814-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
216
引用
收藏
页码：S89 / S90
页数：2
相关论文
共 50 条
  • [1] Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: A case-control study
    Alessandria, C.
    Debernardi-Venon, W.
    Carello, M.
    Ceretto, S.
    Rizzetto, A.
    Marzano, A.
    DIGESTIVE AND LIVER DISEASE, 2009, 41 (04) : 298 - 302
  • [2] A Case for Norepinephrine versus Octreotide and Midodrine in Hepatorenal Syndrome
    Anong, John
    Litchfield, John
    Reddy, Chakradhar
    Borthwick, Thomas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S120 - S120
  • [3] Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1
    Kalambokis, Georgios N.
    Baltayiannis, Gerasimos
    Christodoulou, Dimitrios
    Christou, Leonidas
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (12) : 1428 - 1429
  • [4] Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
    Angeli, P
    Volpin, R
    Gerunda, G
    Craighero, R
    Rone, P
    Merenda, R
    Amodio, P
    Sticca, A
    Caregaro, L
    Maffei-Faccioli, A
    Gatta, A
    HEPATOLOGY, 1999, 29 (06) : 1690 - 1697
  • [5] Combination Treatment With Octreotide, Midodrine, and Albumin Improves Survival in Patients With Type 1 and Type 2 Hepatorenal Syndrome
    Skagen, Catherine
    Einstein, Michael
    Lucey, Michael R.
    Said, Adnan
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (07) : 680 - 685
  • [6] Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide
    Angeli, P
    Volpin, R
    Gerunda, G
    Craighero, R
    Con, P
    Caregaro, L
    Cameriero, V
    Sticca, A
    MaffeiFaccioli, A
    Gatta, A
    HEPATOLOGY, 1997, 26 (04) : 635 - 635
  • [7] Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome.: A case-control study
    Restuccia, T
    Ortega, R
    Guevara, M
    Ginès, P
    Alessandria, C
    Ozdogan, O
    Navasa, M
    Rimola, A
    Garcia-Valdecasas, JC
    Arroyo, V
    Rodés, J
    JOURNAL OF HEPATOLOGY, 2004, 40 (01) : 140 - 146
  • [8] Association of restless legs syndrome in type 2 diabetes: A case-control study
    Merlino, Giovanni
    Fratticci, Lara
    Valente, Mariarosaria
    Del Giudice, Angela
    Noacco, Claudio
    Dolso, Pierluigi
    Cancelli, Iacopo
    Scalise, Anna
    Gigli, Gian Luigi
    SLEEP, 2007, 30 (07) : 866 - 871
  • [9] Efficacy of Midodrine, Octreotide and Albumin (MOA) for Type I Hepatorenal Syndrome (HRS 1)
    Liu, Eashen
    Singhal, Pooja
    Karim, Yasmin K.
    Barton, Franca B.
    Lewis, James H.
    GASTROENTEROLOGY, 2011, 140 (05) : S959 - S959
  • [10] Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome
    Wong, F
    Pantea, L
    Sniderman, K
    HEPATOLOGY, 2004, 40 (01) : 55 - 64
12345